Daniel V LaBarbera

10PUBLICATIONS
22CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersTissue engineeringCancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Mar 12, 2025
Targeted Inhibition of CHD1L by OTI-611 Reprograms Chemotherapy and Targeted Therapy-Induced Cell Cycle Arrest and Suppresses Proliferation to Produce Synergistic Antitumor Effects in Breast and Colorectal Cancer.

Hector Esquer, Qiong Zhou, Daniel V LaBarbera

|Dec 17, 2024
CHD1L Inhibitor OTI-611 Synergizes with Chemotherapy to Enhance Antitumor Efficacy and Prolong Survival in Colorectal Cancer Mouse Models.

Rita Sala, Hector Esquer, Timothy Kellett

|May 15, 2024
Validation of ferroptosis in canine cancer cells to enable comparative oncology and translational medicine.

Priya Chatterji, Gang Xing, Laura Furst

|Feb 22, 2022
Design, Synthesis, and Biological Evaluation of the First Inhibitors of Oncogenic CHD1L.

Brett J Prigaro, Hector Esquer, Qiong Zhou

|Sep 14, 2021
TRIM28 is a transcriptional activator of the mutant TERT promoter in human bladder cancer.

Neeraj Agarwal, Sebastien Rinaldetti, Bassem B Cheikh

|Mar 20, 2021
Isolating and targeting the real-time plasticity and malignant properties of epithelial-mesenchymal transition in cancer.

Hector Esquer, Qiong Zhou, Travis Nemkov

Pageof 2

Frequent Collaborators

2 joint publications

Angelo D'Alessandro

2 joint publications

Hector Esquer

2 joint publications

Paul Awolade

1 joint publications

Joshua M Abbott